QCM
IBRX icon

Quantinno Capital Management’s ImmunityBio IBRX Stock Holding History

Quantinno Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Buy
40,991
+8,782
+27% +$66.5K ﹤0.01% 3138
2026
Q1 		$247K Buy
+32,209
New +$220K ﹤0.01% 3124

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quantinno Capital Management's IBRX Position: Q2 2026 in Review

Quantinno Capital Management increased its ImmunityBio (IBRX) stake by 27% in Q2 2026, buying an estimated $66.5K and bringing the position to 40,991 shares worth $359K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

Quantinno Capital Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Quantinno Capital Management held 40,991 shares of ImmunityBio worth $359K as of Q2 2026.
  • Quantinno Capital Management bought 8,782 ImmunityBio shares in Q2 2026, an estimated $66.5K.
  • ImmunityBio made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #3138 holding.
  • Quantinno Capital Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.